In:
Tropical Journal of Pharmaceutical Research, African Journals Online (AJOL), Vol. 19, No. 7 ( 2020-11-16), p. 1383-1388
Abstract:
Purpose: To investigate the therapeutic effect of baicalein on papillary thyroid cancer (PTC) cells in vitro and its underlying molecular mechanism.Methods: The human PTC cell line TPC-1 was divided into five groups and treated with distilled water or baicalein at 10, 20, 50, or 100 μM. Next, miR-206, miR-206 inhibitor, the respective negative controls of miR-206 and miR-206 inhibitor, RAP1B small interfering RNA (siRNA), and control vector siRNA were synthesized and transfected into TPC-1 cells. Cell viability, migration, and invasion were measured using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) and Transwell assays. miR-206 expression and Ras-related protein (RAP1B) levels were assessed by quantitative real-time reverse transcription-polymerase chain reaction and western blotting, respectively.Results: Baicalein inhibited TPC-1 cell viability, migration and invasion, upregulated miR-206 expression, and reduced the RAP1B level in a concentration-dependent manner (p 〈 0.01). miR-206 negatively regulated RAP1B expression and increased the baicalein-induced reduction of RAP1B expression. Moreover, RAP1B overexpression relieved the suppression of cell viability, migration, and invasion caused by baicalein (p 〈 0.01).Conclusion: Baicalein suppresses cell growth in PTC cells by regulating the miR-206/RAP1B pathway, providing a new therapeutic strategy for PTC treatment. Keywords: Baicalein, Papillary thyroid cancer (PTC), miR-206, RAP1B, Cell viability, Cell invasion
Type of Medium:
Online Resource
ISSN:
1596-9827
,
1596-5996
DOI:
10.4314/tjpr.v19i7.7
Language:
Unknown
Publisher:
African Journals Online (AJOL)
Publication Date:
2020
detail.hit.zdb_id:
2125881-8
SSG:
15,3
Bookmarklink